Oman Veterinary Pharmaceuticals Market Size, Share & Forecast, By Product Type, Animal Type & Distribution Channel, 2026–2031

The Oman Veterinary Pharmaceuticals Market is worth USD 69 million in 2025. The estimate covers veterinary medicines, vaccines, parasiticides, supportive therapies and selected medicated products sold for livestock, poultry, companion animals and equine use in Oman. It excludes veterinary equipment, diagnostics without a pharmaceutical component and internal farm-service costs. The estimate is triangulated from supplier and distributor revenues, veterinary vaccine imports, treatment-dose equivalents and demand from Oman’s animal population. The confidence range is USD 62-76 million, with imported-product pricing and distributor margins creating the largest uncertainty.

The market is projected to grow at a 7.25% CAGR from 2025 to 2031, reaching USD 105 million by 2031. Growth should be faster than the 5.82% historical CAGR recorded during 2020-2025 because vaccines, long-acting formulations and premium companion-animal therapies are gaining mix. Treatment-dose equivalents are forecast to rise from 88 million in 2025 to 122 million in 2031, while price and mix contribute additional value growth. The forecast assumes continuing GCC supply access, formal product registration and no severe disruption to farm economics or disease-control programs.

The largest profit-pool shift will be from commodity anti-infectives toward vaccines, parasiticides, reproductive products and specialized companion-animal therapies. Vaccine revenue share is modeled to increase from 27% in 2025 to 34% by 2031, supported by imported biologicals, recurring immunization schedules and food-safety priorities. Anti-infectives remain essential, but antimicrobial stewardship and residue controls will constrain indiscriminate growth. Suppliers with cold-chain reliability, technical support and strong registration dossiers can capture higher gross margins than distributors focused only on broad-spectrum generics and low-value farm products.

Import and regulatory execution is the most important constraint. Oman’s veterinary pharmaceutical supply is modeled as 89% import-dependent in 2025, and the UAE represented about 64% of veterinary vaccine import value in 2024. Import permits can be valid for only one month, increasing the risk of timing mismatches, stock-outs and working-capital pressure. Smaller suppliers also face dossier, batch, pharmacovigilance and cold-chain requirements that may not be economical for low-volume SKUs. The constraint is therefore operational, not simply regulatory, because compliance quality directly affects revenue continuity.

Oman ranks fourth among the six GCC markets in modeled 2025 veterinary pharmaceutical value, behind Saudi Arabia, the UAE and Kuwait but ahead of Qatar and Bahrain. Its USD 69 million market is smaller than the UAE’s modeled USD 238 million pool, yet Oman’s 7.25% forecast CAGR is above Saudi Arabia’s modeled 6.8% and Kuwait’s 6.4%. Oman benefits from a relatively large small-ruminant base and established UAE re-export links, but its lower domestic manufacturing depth makes import execution and distributor capability more strategically important.

The strongest measurable demand driver is the size and treatment intensity of Oman’s food-animal population. The country recorded approximately 2.59 million goats and 0.67 million sheep in the latest official series, creating a combined base above 3.26 million head. Government data also recorded 417,113 camel treatments in 2021, demonstrating substantial recurring veterinary activity. These animals require parasiticides, vaccines, anti-infectives, nutritional products and reproductive therapies, while poultry and companion animals add higher-frequency and higher-value demand pools. The driver is therefore both volumetric and mix-related.